Lite Strategy (LITS) EBIT Margin (2016 - 2023)
Lite Strategy (LITS) posted EBIT Margin of 84.66% for Q3 2023, up 111.13% on a QoQ basis from 760.47% in Q2 2023, and up 29336.0% year-over-year from N/an in Q3 2022.
Powered by 
Analysis
Lite Strategy (LITS) EBIT Margin (2016 - 2023) Analysis & Trends
Lite Strategy has reported EBIT Margin for 8 years, with the latest figure at 84.66% in Q3 2023.
- On a quarterly basis, EBIT Margin rose 29336.0% year-over-year to 84.66% in Q3 2023; TTM through Jun 2024 was 22.27%, a 9758.0% increase from a year earlier, with the FY2024 full-year figure at 22.27%, up 9758.0% from the prior year.
- EBIT Margin was 84.66% for Q3 2023 at Lite Strategy, up from 760.47% in the prior quarter.
- The five-year high for EBIT Margin was 84.66% in Q3 2023, with the low at 1201.29% in Q4 2019.
- Average EBIT Margin over 5 years is 417.55%, with a median of 208.69% recorded in 2022.
- The sharpest annual moves came in 2019 and 2020: EBIT Margin slumped 62306 bps in 2019, then jumped 108557 bps in 2020.
- Over 5 years, EBIT Margin stood at 1201.29% in 2019, then soared by 90 bps to 125.23% in 2020, then retreated by 19 bps to 148.96% in 2021, then surged by 118 bps to 27.27% in 2022, then surged by 210 bps to 84.66% in 2023.
- The last three EBIT Margin figures came in at 84.66% (Q3 2023), 760.47% (Q2 2023), and 278.1% (Q1 2023), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -25,380.93% |
| 10 | Lite Strategy | 38.03 Mn | 30.49 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2023 | 84.66% |
| Jun 30, 2023 | -760.47% |
| Mar 31, 2023 | -278.10% |
| Dec 31, 2022 | 27.27% |
| Sep 30, 2022 | -208.69% |
| Jun 30, 2022 | -141.90% |
| Mar 31, 2022 | -222.38% |
| Dec 31, 2021 | -148.96% |
| Sep 30, 2021 | -259.19% |
| Jun 30, 2021 | -207.59% |
| Mar 31, 2021 | -202.18% |
| Dec 31, 2020 | -125.23% |
| Sep 30, 2020 | -192.56% |
| Jun 30, 2020 | 45.00% |
| Mar 31, 2020 | -1,000.24% |
| Dec 31, 2019 | -1,201.29% |
| Sep 30, 2019 | -1,091.01% |
| Jun 30, 2019 | -1,040.57% |
| Mar 31, 2019 | -1,010.09% |
| Dec 31, 2018 | -578.23% |